Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Recruiting · NCT06726148 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT06726148 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Florida Cancer Specialists | Fort Myers | United States | 15 |
| Fred Hutch Cancer Research | Seattle | United States | 4 |
| MD Anderson Cancer Center Uni of Te | Houston | United States | 3 |
| Memorial Sloan Kettering | New York | United States | 5 |
| Scri Oncology Partners | Nashville | United States | 156 |
| University of California LA | Los Angeles | United States | 12 |
| WA Uni School Of Med | St Louis | United States | 9 |